Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Després, Jean-Pierre, Golay, Alain, Sjöström, Lars·2005·New England Journal of Medicine
DOI 10.1056/nejmoa044537

Cited by (999)

Items 601–700 of 999

  1. Effects of Acupuncture Therapy on Abdominal Fat and Hepatic Fat Content in Obese Children: A Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy Study
    Hong Zhang, Yun Peng, Zuxiang Liu, Shilian Li, Zhongli Lv, LiFang Tian, Jie Zhu, Xüna Zhao, Min Chen · 2011 · The Journal of Alternative and Complementary Medicine
  2. Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic disorders
    Freek J. Janssen, Mario van der Stelt · 2016 · Bioorganic & Medicinal Chemistry Letters
  3. CB1 allosteric modulators and their therapeutic potential in CNS disorders
    Catharine A. Mielnik, Vincent M. Lam, Ruth A. Ross · 2020 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  4. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19
    Reşat Çınar, Malliga R. Iyer, George Kunos · 2021 · British Journal of Pharmacology
  5. Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls
    Justyna Kuliczkowska-Płaksej, Łukasz Łaczmański, Andrzej Milewicz, Agnieszka Lenarcik, Anna Trzmiel-Bira, Urszula Zaleska–Dorobisz, Felicja Lwow, Lidia Hirnle · 2014 · International Journal of Endocrinology
  6. Drug Treatment for Obesity in the Post-Sibutramine Era
    Bernard M.Y. Cheung · 2011 · Drug Safety
  7. A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low‐Calorie Diet
    Thomas A. Wadden, Ken Fujioka, Søren Toubro, Ira Gantz, Ngozi Erondu, Menghui Chen, Shailaja Suryawanshi, Wendy L. Carofano, Amy O. Johnson‐Levonas, Deborah R. Shapiro et al. · 2010 · Obesity
  8. Chronic administration of AM251 improves albuminuria and renal tubular structure in obese rats
    Kayte A. Jenkin, Lannie O’Keefe, Anna C Simcocks, Esther Grinfeld, Michael L. Mathai, Andrew J. McAinch, Deanne Helena Hryciw · 2015 · Journal of Endocrinology
  9. Association Between Use of Cannabis in Adolescence and Weight Change into Midlife
    Lexie Zhiyan Jin, Anna Rangan, Jesper Mehlsen, Lars Bo Andersen, Sofus Christian Larsen, Berit L. Heitmann · 2017 · PLoS ONE
  10. Treatment of Obesity With “Combination” Pharmacotherapy
    Richard B. Rothman · 2010 · American Journal of Therapeutics
  11. Elevated Free Fatty Acid is Associated with Cardioembolic Stroke Subtype
    Woo‐Keun Seo, Juyeon Kim, Yoo Hwan Kim, Ji Hyun Kim, Kyungmi Oh, Seong‐Beom Koh, Hong Seog Seo · 2011 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  12. Linoleic acid in diets of mice increases total endocannabinoid levels in bowel and liver: modification by dietary glucose
    Soumita Ghosh, Jennifer F. O’Connell, Olga D. Carlson, Isabel González‐Mariscal, Y Kim, Ruin Moaddel, Paritosh Ghosh, Josephine Mary Egan · 2019 · Obesity Science & Practice
  13. Enterocolic increase of cannabinoid receptor type 1 and type 2 and clinical improvement after probiotic administration in dogs with chronic signs of colonic dysmotility without mucosal inflammatory changes
    Giacomo Rossi, Giorgia Gioacchini, G. Pengo, Jan S. Suchodolski, Albert E. Jergens, Karin Allenspach, Alessandra Gavazza, Silvia Scarpona, Sara Berardi, Livio Galosi et al. · 2019 · Neurogastroenterology & Motility
  14. The endocannabinoid system in the adipose organ
    Kwang‐Mook Jung, Lin Lin, Daniele Piomelli · 2021 · Reviews in Endocrine and Metabolic Disorders
  15. Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity
    Sebastiaan Dalle, Moniek Schouten, Gitte Meeus, Lotte Slagmolen, Katrien Koppo · 2022 · Journal of Cellular Physiology
  16. Reversal of Inflammation‐Induced Impairment of Glucose Uptake in Adipocytes by Direct Effect of CB1 Antagonism on Adipose Tissue Macrophages
    Alexandra Miranville, Andreas W. Herling, Gabriele Biemer‐Daub, Marc Dietrich Voss · 2010 · Obesity
  17. The Benefits of Tight Glycemic Control in Type 2 Diabetes Mellitus
    Derek LeRoith, Elliot J. Rayfield · 2007 · Clinical cornerstone
  18. Central and peripheral consequences of the chronic blockade of CB1cannabinoid receptor with rimonabant or taranabant
    Elena Martín‐García, Aurelijus Burokas, Miquel Martín, Fernando Berrendero, Blanca Rubı́, Christoph Kiesselbach, Andrea Heyne, Juan Domingo Gispert, Olga Millán, Rafael J. Maldonado · 2009 · Journal of Neurochemistry
  19. Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
    Pratima Dibba, Andrew A. Li, George T. Cholankeril, Umair Iqbal, Chiranjeevi Gadiparthi, Muhammad Ali Khan, Donghee Kim, Aijaz Ahmed · 2018 · Medicines
  20. Effects of Cannabidiol on Diabetes Outcomes and Chronic Cerebral Hypoperfusion Comorbidities in Middle-Aged Rats
    Amanda Nunes Santiago, Marco Mori, Francisco Silveira Guimarães, Humberto Milani, Rúbia Maria Weffort de Oliveira · 2018 · Neurotoxicity Research
  21. The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling
    Inmaculada Ruz‐Maldonado, Bo Liu, Patricio Atanes, Attilio Pingitore, Guo Cai Huang, Pratik Choudhary, Shanta Jean Persaud · 2020 · Cellular and Molecular Life Sciences
  22. Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test
    Maria Flavia Barbano, Anna Castañé, Elena Martín‐García, Rafael J. Maldonado · 2009 · Psychopharmacology
  23. The prevention and treatment of metabolic syndrome and high-risk obesity
    Behzad Molavi, Neda Rasouli, Philip A. Kern · 2006 · Current Opinion in Cardiology
  24. Medical Therapy for Obesity—Current Status and Future Hopes
    George A. Bray · 2007 · Medical Clinics of North America
  25. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant
    Andreas W. Herling, Susanne Kilp, H. P. Juretschke, C Neumann-Haefelin, Martin Gerl, Werner Kramer · 2008 · International Journal of Obesity
  26. Regulation of adipocyte autophagy — The potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I
    Shuai Wang, Daoquan Peng · 2012 · Lipids in Health and Disease
  27. Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution
    M. Frost, Torben Leo Nielsen, Kristian Wraae, Carlos Hagen, Elke Piters, Sigri Beckers, Fenna de Freitas, Kim Brixen, Wim Van Hul, Marianne Andersen · 2010 · European Journal of Endocrinology
  28. Medical Management of Obesity and its Complications
    Ian Douglas Caterson · 2009 · Annals of the Academy of Medicine Singapore
  29. Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Safety, Tolerability, and Therapeutic Potential
    Benjamin Adam Steinberg, Christopher Paul Cannon · 2007 · The American Journal of Cardiology
  30. Acute Overactive Endocannabinoid Signaling Induces Glucose Intolerance, Hepatic Steatosis, and Novel Cannabinoid Receptor 1 Responsive Genes
    Maxwell A. Ruby, Daniel K. Nomura, Carolyn S. S. Hudak, Anne Barber, John E. Casida, Ronald M. Krauss · 2011 · PLoS ONE
  31. The Effect of CB1 Antagonism on Hepatic Oxidative/Nitrosative Stress and Inflammation in Nonalcoholic Fatty Liver Disease
    Bojan Z. Jorgačević, Danijela B. Vučević, Janko Samardžić, Dušan R. Mladenović, Milena N. Vesković, Dušan Vukićević, Rada Ješić, Tatjana S. Radosavljević · 2020 · Current Medicinal Chemistry
  32. Peripheral Hybrid CB1R and iNOS Antagonist MRI-1867 Displays Anti-Fibrotic Efficacy in Bleomycin-Induced Skin Fibrosis
    Charles N. Zawatsky, Joshua K. Park, Jasmina Abdalla, George Kunos, Malliga R. Iyer, Reşat Çınar · 2021 · Frontiers in Endocrinology
  33. CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors
    Morvarid Kabir, Malini S. Iyer, Joyce M. Richey, Orison O. Woolcott, Isaac Asare Bediako, Qiang Wu, Stella P. Kim, Darko Stefanovski, Cathryn M. Kolka, Isabel R. Hsu et al. · 2015 · American Journal of Physiology-Endocrinology and Metabolism
  34. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk
    David R. Janero, Loren Lindsley, Kiran V. Vemuri, Alexandros Makriyannis · 2011 · Expert Opinion on Drug Discovery
  35. Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats
    Kelly S. Sink, Kristen N. Segovia, Eric J. Nunes, Lyndsey E. Collins, Kiran V. Vemuri, Ganesh A. Thakur, Alexandros Makriyannis, John D. Salamone · 2009 · Psychopharmacology
  36. The Endocannabinoid System and the Control of Glucose Homeostasis
    Rubén Nogueiras, F. Rohner‐Jeanrenaud, Stephen C. Woods, Matthias H. Tschöp · 2008 · Journal of Neuroendocrinology
  37. Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice
    Yulin Liao, Jianping Bin, Masanori Asakura, Wanling Xuan, Baihe Chen, Qiaobing Huang, Dingli Xu, Catherine A. Ledent, Seiji Takashima, Masafumi Kitakaze · 2011 · European Heart Journal
  38. Endocannabinoids and Metabolic Disorders
    Blandine Gatta‐Cherifi, Daniela Cota · 2015 · Handbook of experimental pharmacology
  39. Peripheral Metabolic Effects of Endocannabinoids and Cannabinoid Receptor Blockade
    Stefan Engeli · 2008 · Obesity Facts
  40. Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
    Christoph Schindler · 2007 · Therapeutic Advances in Cardiovascular Disease
  41. Endocannabinoids and Their Role in Fatty Liver Disease
    Ariane Mallat, Sophie Lotersztajn · 2010 · Digestive Diseases
  42. Cannabinoid-1 receptor antagonists in type-2 diabetes
    André Jacques Scheen · 2007 · Best Practice & Research Clinical Endocrinology & Metabolism
  43. Obesity: Person and Population
    Mark B. Cope, David B. Allison · 2006 · Obesity
  44. Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity
    Alexandru Vasincu, Răzvan-Nicolae Rusu, Daniela Carmen Ababei, Monica Neamţu, Oana Dana Arcan, Ioana Macadan, Sorin Ioan Beşchea Chiriac, Walther Bild, Veronica Bild · 2023 · Biomedicines
  45. CNS Opioid Signaling Separates Cannabinoid Receptor 1-Mediated Effects on Body Weight and Mood-Related Behavior in Mice
    Sarah Haas Lockie, Traci A. Czyzyk, Nilika Chaudhary, Diego Pérez–Tilve, Stephen C. Woods, Brian J. Oldfield, Michael A. Statnick, Matthias H. Tschöp · 2011 · Endocrinology
  46. A review of late-stage CNS drug candidates for the treatment of obesity
    David J. Heal, Jane Gosden, Sharon L. Smith · 2012 · International Journal of Obesity
  47. Metabolic syndrome and chronic kidney disease
    Dipankar M. Bhowmik, SC Tiwari · 2008 · Indian Journal of Nephrology
  48. Pharmacological Treatment of Obesity in Children and Adolescents: Present and Future
    Lorenzo Iughetti, China Mariachiara, Rossella Berri, Barbara Predieri · 2010 · Journal of Obesity
  49. Weight reduction for treatment of obesity-associated hypertension: Nuances and challenges
    Allyn L. Mark · 2007 · Current Hypertension Reports
  50. High-density lipoprotein levels and risk of cardiovascular events
    Gian Francesco Mureddu, Filippo Brandimarte, Leonardo De Luca · 2011 · Journal of Cardiovascular Medicine
  51. The utility of behavioral economics in expanding the free-feed model of obesity
    Erin B. Rasmussen, Stephen H. Robertson, Luis R. Rodriguez · 2016 · Behavioural Processes
  52. Medications for Weight Reduction
    George A. Bray · 2008 · Endocrinology and Metabolism Clinics of North America
  53. Efecto de una intervención global sobre el control integral de múltiples factores de riesgo en pacientes con alto o muy alto riesgo cardiovascular. Estudio CIFARC 2
    Andrés de la Peña Fernández, Bernardino Roca, José Ignacio Cuende, José Ramón Calabuig Alborch, Julio Montes Santiago, Manuel Muñoz Rodríguez, M. Piedracausa Selfa, C. Suárez Fernández · 2007 · Revista Clínica Española
  54. Effect of the Cannabinoid Receptor‐1 Antagonist Rimonabant on Inflammation in Mice With Diet‐Induced Obesity
    Qun Wang, Xiaoyuan Dai Perrard, Jerry L. Perrard, Amir Mansoori, C. Wayne Smith, Christie Mitchell Ballantyne, Huaizhu Wu · 2010 · Obesity
  55. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity
    John R. Hadcock, David A. Griffith, Phillip Iredale, Phillip A. Carpino, Robert L. Dow, Shawn C. Black, Rebecca O’Connor, Denise Gautreau, Jeffrey S. Lizano, Karen M. Ward et al. · 2010 · Biochemical and Biophysical Research Communications
  56. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model
    J. Jaime, Ipek Özer Stillman, Aurélie Danel, Denis Getsios, P McEwan · 2007 · Journal of Medical Economics
  57. Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies
    Louis J. Aronne, William Virgil Brown, Kathy K. Isoldi · 2007 · Journal of clinical lipidology
  58. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk?
    Jeetesh V. Patel, Hoong Sern Lim, Elizabeth A. Hughes, Gregory Y.H. Lip · 2006 · Journal of Human Hypertension
  59. Dyslipidemia and glucose dysregulation in overweight and obese patients
    Derek LeRoith · 2007 · Clinical cornerstone
  60. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes
    Anthony H Barnett · 2008 · Diabetes and Vascular Disease Research
  61. Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery
    Siyuan Shen, Chao Wu, Zhiqian Yang, Kexin Wang, Zhenhua Shao, Wei Yan · 2025 · Acta Pharmacologica Sinica
  62. Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif
    Laurent Hortala, Murielle L. Rinaldi, Christian Congy, Laurent G. Boulu, Freddy Sadoun, Gérard Fabre, Olivier Finance, Francis Barth · 2010 · Bioorganic & Medicinal Chemistry Letters
  63. Endocannabinoid tone is higher in healthy lean South Asian than white Caucasian men
    Vasudev Kantae, Kimberly J. Nahon, Maaike E. Straat, Leontine E. H. Bakker, Amy C. Harms, Mario van der Stelt, Thomas Hankemeier, Ingrid M. Jazet, Mariëtte R. Boon, Patrick C.N. Rensen · 2017 · Scientific Reports
  64. Naturally Occurring Cannabinoids and their Role in Modulation of Cardiovascular Health
    Elnaz Karimian Azari, Aileen Kerrigan, Annalouise O’Connor · 2020 · Journal of Dietary Supplements
  65. Rimonabant: more than an anti‐obesity drug?
    Barbara Costa · 2007 · British Journal of Pharmacology
  66. Impact of Weight-Loss Medications on the Cardiovascular System
    Benoît Drolet, Chantale Simard, Paul Poirier · 2007 · American Journal of Cardiovascular Drugs
  67. Prevention and treatment of nonalcoholic fatty liver disease
    Giovanni Targher, Alessandro Bellis, Paolo Fornengo, Maria Francesca Ciaravella, Isabella Pichiri, Paolo Cavallo Perin, Bruno Trimarco, Giulio Marchesini · 2010 · Digestive and Liver Disease
  68. The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity
    Paspala, Ioanna, Katsiki, Niki, Kapoukranidou, Dorothea, Mikhailidis, Dimitri P, Tsiligiroglou-Fachantidou, Anna · 2012 · The Open Cardiovascular Medicine Journal
  69. Obesity-Related Cardiometabolic Complications
    Christopher Paul Cannon · 2008 · Clinical cornerstone
  70. Insulin resistance and lipid disorders
    Roberto Miccoli, Dieuwke De Keyzer, David Giuseppe Penno, David Stefano Del Prato · 2008 · Future Lipidology
  71. Update in prevention of atherosclerotic heart disease: management of major cardiovascular risk factors.
    Abel Romero‐Corral, Virend Kristen Somers, Josef K. Korinek, Justo Sierra‐Johnson, Randal J. Thomas, Thomas G. Allison, Francisco Alejandro López-Jiménez · 2006 · PubMed
  72. Liver Illness and Psychiatric Patients
    Paul Carrier, Marilyne Debette‐Gratien, Murielle F. Girard, Jérémie Jacques, Philippe Nubukpo, Véronique Loustaud-Ratti · 2016 · Hepatitis Monthly
  73. Rimonabant: obituary for a wonder drug
    S. Matthijs Boekholdt, Ron J.G. Peters · 2010 · The Lancet
  74. Rimonabant: The role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients
    Christopher T. Dibble, Eli V. Gelfand, Christopher Paul Cannon · 2007 · Current Atherosclerosis Reports
  75. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes
    Shira Hirsch, Liad Hinden, Meital Ben-David Naim, Saja Baraghithy, Anna Permyakova, Shahar Azar, Taher Nasser, Emma Portnoy, Majd Agbaria, Alina Nemirovski et al. · 2022 · Journal of Controlled Release
  76. Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease
    Bojan Z. Jorgačević, Dušan R. Mladenović, Milica Ninković, Milena N. Vesković, Vesna V. Dragutinović, Aleksandar Vatazević, Danijela B. Vučević, Rada Ješić-Vukićević, Tatjana S. Radosavljević · 2015 · Oxidative Medicine and Cellular Longevity
  77. Novel sterically hindered cannabinoid CB1 receptor ligands
    Paolo Urbani, Maria Grazia Cascio, Anna Ramunno, Tiziana Bisogno, Carmela Saturnino, Vincenzo Di Marzo · 2008 · Bioorganic & Medicinal Chemistry
  78. Emerging pharmacotherapies for smoking cessation
    Candice L. Garwood, Lisa A. Potts · 2007 · American Journal of Health-System Pharmacy
  79. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats
    Ikram Merroun, Cristina Sánchez‐González, Rosario Martínez, Carlos López-Chaves, Jesus María Porres, Pilar Aranda, Juan Llopis, Milagros Galisteo, Antonio Zarzuelo, Mohammed Errami et al. · 2013 · Metabolism
  80. Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology
    Norberto Carlos Chávez-Tapia, Félix Ignacio Téllez-Ávila, Giorgio Bedogni, Lory Saveria Crocè, Flora Masutti, Claudio Tiribelli · 2009 · BMC Gastroenterology
  81. Update in the management of obesity.
    Ketut Suastika · 2006 · PubMed
  82. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome
    Christopher Paul Cannon · 2007 · Clinical cornerstone
  83. Current and novel approaches to the drug therapy of obesity
    Jean‐Philippe Chaput, Angelo Tremblay · 2006 · European Journal of Clinical Pharmacology
  84. Pharmacotherapy in pediatric obesity: Current agents and future directions
    Abigail B. Wald, Naveen K. Uli · 2009 · Reviews in Endocrine and Metabolic Disorders
  85. A History of Drug Discovery
    F. Chast · 2008 · Elsevier eBooks
  86. Anti-obesity drugs
    Robert F. Kushner · 2008 · Expert Opinion on Pharmacotherapy
  87. Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity
    Danielle Duffy, Daniel James Rader · 2007 · Trends in Cardiovascular Medicine
  88. Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses
    Subramaniam Jayanthi, S Buie, S Moore, Ronald I. Herning, WARREN E. BETTER, N M Wilson, Carlo S. Contoreggi, Jean Lud Cadet · 2008 · Molecular Psychiatry
  89. Next-generation therapeutics for diabetic kidney disease
    Tae Won Yi, Vikas S. Sridhar, Jennifer Scott, Massimo Nardone, David Z.I. Cherney · 2026 · Nature Reviews Nephrology
  90. Psychosocial and Pharmacological Interventions for the Treatment of Cannabis Use Disorder
    Pamela Sabioni, Bernard Le Foll · 2019 · FOCUS The Journal of Lifelong Learning in Psychiatry
  91. Adiponectin: An Indicator for Metabolic Syndrome
    Somaye Yosaee, Mahmoud Khodadost, Alireza Esteghamati, John Roger Speakman, Kurosh Djafarian, Vida Bitarafan, Farzad Shidfar · 2020 · Iranian Journal of Public Health
  92. From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis
    Beier Jiang, Xingwu Jiang, Qiansen Zhang, Qiuwen Liang, Zi-Liang Qiu, Xiang-Bai Sun, Junjie Yang, Si Chen, Chunyang Yi, Xiaolei Chai et al. · 2020 · Journal of Medicinal Chemistry
  93. Antiobesity Effects of Melanin-Concentrating Hormone Receptor 1 (MCH-R1) Antagonists
    Hyae Gyeong Cheon · 2011 · Handbook of experimental pharmacology
  94. Treatment of Dyslipidemia to Reduce Cardiovascular Risk in Patients with Multiple Risk Factors
    Christie Mitchell Ballantyne · 2007 · Clinical cornerstone
  95. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice
    Kim S. Bell-Anderson, Leyla J. Aouad, Helen Williams, F. Rodríguez Sanz, Jenny L. Phuyal, Claire Z. Larter, Geoffrey C. Farrell, Ian Douglas Caterson · 2011 · International Journal of Obesity
  96. Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat
    Wei Jing Liu, Heung Yong Jin, Ji Hyun Park, Hong Sun Baek, Tae Sun Park · 2010 · European Journal of Pharmacology
  97. Endocannabinoid system and its implications for obesity and cardiometabolic risk
    Richard W. Nesto, Ken Mackie · 2008 · European Heart Journal Supplements
  98. Risk of major adverse cardiovascular events in patients with metabolic syndrome after revascularization: A meta-analysis of eighteen cohorts with 18457 patients
    Hongtao Tie, Rui Shi, Zhen-Han Li, Min Zhang, Cheng Zhang, Qingchen Wu · 2015 · Metabolism
  99. Single-nucleotide polymorphism rs1761667 in the CD36 gene is associated with orosensory perception of a fatty acid in obese and normal-weight Moroccan subjects
    Habiba Bajit, O. Ait Si Mohammed, Yasmine Guennoun, Souad Benaich, Elarbi Bouaiti, Hakim Belghiti, M. Mrabet, Elmostafa El Fahime, Noureddine El Haloui, Naima Saeid et al. · 2020 · Journal of Nutritional Science
  100. Cannabinoid type 1 receptor mediates depot-specific effects on differentiation, inflammation and oxidative metabolism in inguinal and epididymal white adipocytes
    Isabel Viola Wagner, Nina Perwitz, Maren Drenckhan, Hendrik Lehnert, J Klein · 2011 · Nutrition and Diabetes